$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Device financing during 2015's third quarter reached $1.4 billion, a 22% dip from Q2's $1.8 billion total. (See Exhibit 1.) Late-stage venture capital rounds represented most of the Q3 fundraising, bringing in $511 million, or 36% of the total – a significant increase over Q2's $275 million in late-stage VC rounds (which made up just 15% of that quarter's aggregate financing).
Exhibit 1
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
